Silicon Valley Bank offers new tool to value biotech startups
| April 25, 2008 |  View for printing |
New data by Silicon Valley Bank's http://www.svb.com/ valuations group attempts to bring objectivity to the relatively unscientific process of valuing early-stage biotech companies.
The challenge is that these companies are generally pre-revenue and potentially years away from profitability -- if that's in their future at all. Unknown factors such as timing, amount, price and terms of future rounds of financing make valuations something of a guessing game.
Silicon Valley / San Jose Business Journal - by Lindsay Riddell
Full Story: http://sanjose.bizjournals.com/sanjo ... 400^1622067
No reader comments so far. Be the first to comment by clicking the button below.
Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.
